Sawcer SJ, Maranian M, Singlehurst S, et al. Enhancing linkage analysis of complex disorders: an evaluation of high-density genotyping. Hum Mol Genet. 2004;13(17):1943-9. doi:10.1093/hmg/ddh202
Fancy SPJ, Harrington EP, Yuen TJ, et al. Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci. 2011;14(8):1009-16. doi:10.1038/nn.2855
Fancy SPJ, Kotter MR, Harrington EP, et al. Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Exp Neurol. 2010;225(1):18-23. doi:10.1016/j.expneurol.2009.12.020
Patsopoulos NA, Bayer Pharma MS Genetics Working Group, Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist, et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011;70(6):897-912. doi:10.1002/ana.22609
Fancy SPJ, Glasgow SM, Finley M, Rowitch DH, Deneen B. Evidence that nuclear factor IA inhibits repair after white matter injury. Ann Neurol. 2012;72(2):224-33. doi:10.1002/ana.23590
Ottoboni L, Keenan BT, Tamayo P, et al. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012;4(153):153ra131. doi:10.1126/scitranslmed.3004186
Isobe N, Gourraud PA, Harbo HF, et al. Genetic risk variants in African Americans with multiple sclerosis. Neurology. 2013;81(3):219-27. doi:10.1212/WNL.0b013e31829bfe2f
Querol L, Clark PL, Bailey MA, et al. Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis. Neurology. 2013;81(11):956-63. doi:10.1212/WNL.0b013e3182a43b48
Ottoboni L, Frohlich IY, Lee M, et al. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013;81(22):1891-9. doi:10.1212/01.wnl.0000436612.66328.8a
Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet. 2008;17(R2):R116-21. doi:10.1093/hmg/ddn246